Insight, China's Pharmaceutical Industry

China’s Basic Medical Insurance Covers 1.33 Billion in 2025 – NHSA Reports RMB 3.6 Trillion Fund Inflows, 114 New Drugs Added to NRDL

China’s National Healthcare Security Administration (NHSA) released its 2025 Healthcare Security Development Statistical Bulletin, revealing...

Company Drug

Novartis’ Cosentyx Wins FDA Pediatric Approval – Only IL-17A Inhibitor for Hidradenitis Suppurativa in Adolescents 12+

Fineline Cube Mar 16, 2026

Novartis (NYSE: NVS) announced that Cosentyx (secukinumab) received U.S. FDA approval for treating pediatric patients aged...

Company Drug

Cutia Therapeutics’ CU-40105 Wins NMPA Approval – Topical Dutasteride Targets Androgenetic Alopecia with Reduced Systemic Exposure

Fineline Cube Mar 16, 2026

Cutia Therapeutics announced NMPA clearance to initiate a clinical study for CU-40105, a topical dutasteride...

Company Drug Medical Device

J&J’s Erda-iDRS Shows 89% Complete Response in NMIBC – Intravesical Erdafitinib System Advances to Phase II/III

Fineline Cube Mar 16, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced positive Phase I results for Erda-iDRS, an investigational...

Company Drug

BeBetter Medicine’s Ifupinostat Wins NMPA Approval for PTCL Trial – First HDAC/PI3Kα Dual Inhibitor Enters First-Line Lymphoma Study

Fineline Cube Mar 16, 2026

Guangzhou BeBetter Medicine Technology Co., Ltd (SHA: 688759) announced NMPA clearance to initiate a clinical...

Company Drug

Abbisko’s Irpagratinib Doses First Patient in Phase II HCC Trial – FGFR4 Inhibitor Plus Toripalimab/Bevacizumab Targets First-Line Liver Cancer

Fineline Cube Mar 16, 2026

Abbisko Therapeutics Co., Ltd (HKG: 2256) announced first patient dosing in a Phase II clinical...

Company

Junshi Biosciences Reports RMB 2.5 Billion 2025 Revenue – Toripalimab Drives 40% Drug Sales Growth as Losses Narrow

Fineline Cube Mar 16, 2026

Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) released 2025 financial results, recording RMB...

Company Drug

YolTech’s YOLT-202 Wins FDA Phase II/III Approval – In Vivo Base Editing Gene Therapy Targets Alpha-1 Antitrypsin Deficiency

Fineline Cube Mar 16, 2026

YolTech Therapeutics announced FDA clearance to initiate an open-label, single-dose expansion Phase II/III clinical study...

Company Drug

GSK’s Arexvy Wins FDA Label Expansion – RSV Vaccine Now Covers High-Risk Adults Aged 18-49

Fineline Cube Mar 16, 2026

GlaxoSmithKline (GSK, NYSE: GSK) announced FDA approval for a label expansion of its adjuvanted respiratory...

Company Drug

Biogen’s Salanersen Shows 75% NfL Reduction in SMA Phase Ib – Once-Yearly ASO Advances to Phase III

Fineline Cube Mar 16, 2026

Biogen Inc. (NASDAQ: BIIB) presented supplemental Phase Ib data for salanersen, its investigational antisense oligonucleotide...

Company Deals

Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market

Fineline Cube Mar 13, 2026

Kintor Pharmaceutical Limited (HKG: 9939) entered into a strategic cooperation agreement with Zhejiang Fonow Medicine...

Company Drug

Sino Biopharm’s TQB3454 Hits Phase III Endpoints in IDH1+ Biliary Tract Cancer – China’s First IDH1 Inhibitor Poised for NDA Filing

Fineline Cube Mar 13, 2026

Sino Biopharmaceutical (HKG: 1177) announced that TQB3454 Tablets, a Category 1 innovative drug developed by...

Company Drug

CMS Launches Opzelura Nationwide – First Topical JAK Inhibitor for Vitiligo Reaches 1,300+ Pharmacies Across 30 Chinese Provinces

Fineline Cube Mar 13, 2026

China Medical System Holdings (CMS; HKG: 0867) announced that first prescriptions of Ruxolitinib Phosphate Cream...

Company Drug

Essight Bio’s ES502 Wins FDA Phase I Approval – First TCR×CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic

Fineline Cube Mar 13, 2026

Shanghai Essight Biotechnology Co., Ltd. announced that ES502 Injection has received FDA approval to proceed...

Company Deals

APC Group and Youcare Pharmaceutical Forge Strategic Partnership – Global Distribution Alliance Targets China-India Pharma Collaboratio

Fineline Cube Mar 13, 2026

APC Group and Youcare Pharmaceutical Group (SHA: 688658) signed a strategic cooperation framework agreement establishing...

Company Deals

WuXi Biologics Partners with Earendil Labs – Integrated CDMO Services for Bispecific Antibodies and ADCs Targeting Autoimmune and Oncology Indications

Fineline Cube Mar 13, 2026

WuXi Biologics (HKG: 2269) announced a strategic cooperation agreement with Earendil Labs, the overseas subsidiary...

Company Deals

Everest Medicines Reports Positive Phase IIa Data for VIS-101 – Dual VEGF-A/Ang-2 Inhibitor Shows Best-in-Class Potential in wAMD

Fineline Cube Mar 13, 2026

Everest Medicines (HKG: 1952) announced positive topline results from its Phase IIa study of VIS-101,...

Company Deals

Luye Pharma Signs Strategic Partnership with Sinopharm – Mimeixin Distribution Deal Targets China’s Severe Pain Market

Fineline Cube Mar 13, 2026

Luye Pharma Group Limited (HKG: 2186) announced a strategic cooperation agreement with Sinopharm Group Co.,...

Company Deals

Porton Advanced Partners with T&L Biotechnology – CGT One-Stop Solution Targets Global Cell and Gene Therapy Market

Fineline Cube Mar 13, 2026

Porton Advanced, a subsidiary of Porton Pharma Solutions, Ltd, announced a strategic partnership with T&L...

Medical Device

China NMPA Approves World’s First Invasive BCI Medical Device – Brain-Computer Interface Hand Motor System Targets Spinal Cord Injury Patients

Fineline Cube Mar 13, 2026

China’s National Medical Products Administration (NMPA) granted registration approval for the “Implantable Brain-Computer Interface Hand...

Insight, China's Pharmaceutical Industry

Shyndec Pharmaceutical Licenses Eisai Myonal Generic from ScienPharm – RMB 10.5 Million Deal Targets Muscle Relaxant Market

MSD Reportedly Eyes $6 Billion Terns Pharma Acquisition – BCR-ABL Inhibitor TERN-701 Targets Post-Keytruda Oncology Pipelinew333333

Asieris Pharma Partners with SPH Keyuan to Commercialize Cevira – World’s First Non‑Surgical Cervical Precancer Treatment Launches in China

Sciwind Biosciences Files Hong Kong IPO Prospectus – GLP‑1 Obesity Pipeline Targets R&D Funding for Weight Management Franchise

Kali Therapeutics Licenses KT501 to Sanofi – $1.23B Deal for Trispecific T-Cell Engager Targets Autoimmune Diseases

Zhifei Bio Initiates Phase I Study for DTaP-Hib Quadrivalent Vaccine – Component Combination Targets Pediatric Immunization Compliance

Changchun High-Tech Wins FDA Orphan Drug Designation for GenSci128 – TP53 Y220C Reactivator Targets Gastric Cancer

China’s Basic Medical Insurance Covers 1.33 Billion in 2025 – NHSA Reports RMB 3.6 Trillion Fund Inflows, 114 New Drugs Added to NRDL

Novartis’ Cosentyx Wins FDA Pediatric Approval – Only IL-17A Inhibitor for Hidradenitis Suppurativa in Adolescents 12+

Cutia Therapeutics’ CU-40105 Wins NMPA Approval – Topical Dutasteride Targets Androgenetic Alopecia with Reduced Systemic Exposure

J&J’s Erda-iDRS Shows 89% Complete Response in NMIBC – Intravesical Erdafitinib System Advances to Phase II/III

BeBetter Medicine’s Ifupinostat Wins NMPA Approval for PTCL Trial – First HDAC/PI3Kα Dual Inhibitor Enters First-Line Lymphoma Study

Abbisko’s Irpagratinib Doses First Patient in Phase II HCC Trial – FGFR4 Inhibitor Plus Toripalimab/Bevacizumab Targets First-Line Liver Cancer

Junshi Biosciences Reports RMB 2.5 Billion 2025 Revenue – Toripalimab Drives 40% Drug Sales Growth as Losses Narrow

YolTech’s YOLT-202 Wins FDA Phase II/III Approval – In Vivo Base Editing Gene Therapy Targets Alpha-1 Antitrypsin Deficiency

GSK’s Arexvy Wins FDA Label Expansion – RSV Vaccine Now Covers High-Risk Adults Aged 18-49

Biogen’s Salanersen Shows 75% NfL Reduction in SMA Phase Ib – Once-Yearly ASO Advances to Phase III

Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market

Sino Biopharm’s TQB3454 Hits Phase III Endpoints in IDH1+ Biliary Tract Cancer – China’s First IDH1 Inhibitor Poised for NDA Filing

CMS Launches Opzelura Nationwide – First Topical JAK Inhibitor for Vitiligo Reaches 1,300+ Pharmacies Across 30 Chinese Provinces

Essight Bio’s ES502 Wins FDA Phase I Approval – First TCR×CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic

APC Group and Youcare Pharmaceutical Forge Strategic Partnership – Global Distribution Alliance Targets China-India Pharma Collaboratio

WuXi Biologics Partners with Earendil Labs – Integrated CDMO Services for Bispecific Antibodies and ADCs Targeting Autoimmune and Oncology Indications

Everest Medicines Reports Positive Phase IIa Data for VIS-101 – Dual VEGF-A/Ang-2 Inhibitor Shows Best-in-Class Potential in wAMD

Luye Pharma Signs Strategic Partnership with Sinopharm – Mimeixin Distribution Deal Targets China’s Severe Pain Market

Porton Advanced Partners with T&L Biotechnology – CGT One-Stop Solution Targets Global Cell and Gene Therapy Market

China NMPA Approves World’s First Invasive BCI Medical Device – Brain-Computer Interface Hand Motor System Targets Spinal Cord Injury Patients

You Missed

Shyndec Pharmaceutical Licenses Eisai Myonal Generic from ScienPharm – RMB 10.5 Million Deal Targets Muscle Relaxant Market

MSD Reportedly Eyes $6 Billion Terns Pharma Acquisition – BCR-ABL Inhibitor TERN-701 Targets Post-Keytruda Oncology Pipelinew333333

Zhifei Bio Initiates Phase I Study for DTaP-Hib Quadrivalent Vaccine – Component Combination Targets Pediatric Immunization Compliance

Changchun High-Tech Wins FDA Orphan Drug Designation for GenSci128 – TP53 Y220C Reactivator Targets Gastric Cancer